Biomarin Pharmaceutical (MIL:1BMRN) Additional Paid-In Capital : €5,170 Mil(As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Additional Paid-In Capital?

Biomarin Pharmaceutical's quarterly additional paid-in capital declined from Sep. 2023 (€5,194 Mil) to Dec. 2023 (€5,146 Mil) but then increased from Dec. 2023 (€5,146 Mil) to Mar. 2024 (€5,170 Mil).

Biomarin Pharmaceutical's annual additional paid-in capital increased from Dec. 2021 (€4,594 Mil) to Dec. 2022 (€5,102 Mil) and increased from Dec. 2022 (€5,102 Mil) to Dec. 2023 (€5,146 Mil).

Biomarin Pharmaceutical Additional Paid-In Capital Historical Data

The historical data trend for Biomarin Pharmaceutical's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Additional Paid-In Capital Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

4,349.44

4,104.58

4,594.48

5,102.22

5,145.80

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															5,060.29	5,070.92	5,193.58	5,145.80	5,169.72

Biomarin Pharmaceutical Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Biomarin Pharmaceutical Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical (MIL:1BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BMRN:USA BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (MIL:1BMRN) Headlines

No Headlines